These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
90 related articles for article (PubMed ID: 3069285)
21. Validation of a conscious rat model for the discovery of novel agents that inhibit gastric acid secretion. Campbell CA; Gaskin PJ; Darton J; Chiu P; Lee K; McLean PG Eur J Pharmacol; 2008 Jul; 589(1-3):260-3. PubMed ID: 18571645 [TBL] [Abstract][Full Text] [Related]
22. Efficacy, safety, and cost issues in managing patients with gastroesophageal reflux disease. Garnett WR Am J Hosp Pharm; 1993 Apr; 50(4 Suppl 1):S11-8. PubMed ID: 8097363 [TBL] [Abstract][Full Text] [Related]
23. [25 years of gastric acid blockers]. Lamers CB Ned Tijdschr Geneeskd; 1999 Dec; 143(50):2501-4. PubMed ID: 10627749 [TBL] [Abstract][Full Text] [Related]
24. Control of gastric acid with high dose H2-receptor antagonists after omeprazole failure: report of two cases. Leite LP; Just RJ; Castell DO; Lagerström PO Am J Gastroenterol; 1995 Oct; 90(10):1874-7. PubMed ID: 7572913 [TBL] [Abstract][Full Text] [Related]
26. Omeprazole in the treatment of peptic ulcers and gastroesophageal reflux disease. Cappell MS N J Med; 1992 Oct; 89(10):762-4. PubMed ID: 1461581 [TBL] [Abstract][Full Text] [Related]
27. The pharmacology of esomeprazole and its role in gastric acid related diseases. Saccar CL Expert Opin Drug Metab Toxicol; 2009 Sep; 5(9):1113-24. PubMed ID: 19606942 [TBL] [Abstract][Full Text] [Related]
29. Effect of omeprazole, a substituted benzimidazole, on 24-h intragastric acidity in patients with peptic ulcer disease. Naesdal J; Bodemar G; Walan A Scand J Gastroenterol; 1984 Oct; 19(7):916-22. PubMed ID: 6531660 [TBL] [Abstract][Full Text] [Related]
30. Effects of omeprazole therapy on peptic disease and serum gastrin levels in hemodialysis patients. A preliminary study. Montemurro NE; Di Maggio A; Loperfido A; Franceschi M; Scatizzi A Clin Nephrol; 1993 Nov; 40(5):296-8. PubMed ID: 8281719 [TBL] [Abstract][Full Text] [Related]
32. [The second generation of gastric antisecretory agents: omeprazole]. Souquet JC Rev Med Interne; 1988; 9(5):538-44. PubMed ID: 3067302 [TBL] [Abstract][Full Text] [Related]
33. Basal, sham feed and pentagastrin stimulated gastric acid, pepsin and electrolytes after omeprazole 20 mg and 40 mg daily. Thompson JN; Barr JA; Collier N; Spencer J; Bush A; Cope L; Gribble RJ; Baron JH Gut; 1985 Oct; 26(10):1018-24. PubMed ID: 3932137 [TBL] [Abstract][Full Text] [Related]
34. The physiological background behind and course of development of the first proton pump inhibitor. Lundell L Scand J Gastroenterol; 2015 Jun; 50(6):680-4. PubMed ID: 25857639 [TBL] [Abstract][Full Text] [Related]
35. Omeprazole in the treatment of Zollinger-Ellison syndrome: a 4-year international study. Lloyd-Davies KA; Rutgersson K; Sölvell L Aliment Pharmacol Ther; 1988 Feb; 2(1):13-32. PubMed ID: 2979229 [TBL] [Abstract][Full Text] [Related]
36. Risk-benefit assessment of omeprazole in the treatment of gastrointestinal disorders. Creutzfeldt W Drug Saf; 1994 Jan; 10(1):66-82. PubMed ID: 8136088 [TBL] [Abstract][Full Text] [Related]
37. Clinical impact of H+, K+-ATP-ase inhibitors. Proceedings of a symposium. Maastricht, November 25, 1988. Digestion; 1989; 44 Suppl 1():1-95. PubMed ID: 2606279 [No Abstract] [Full Text] [Related]
38. Will omeprazole succeed in refractory duodenal ulcer when the histamine receptor antagonists fail? Bardhan KD Natl Med J India; 1991; 4(3):130-131. PubMed ID: 29764084 [No Abstract] [Full Text] [Related]
39. The Dutch contribution to research and clinical experience with omeprazole. Lamers CB; Dols DM Digestion; 1989; 44 Suppl 1():1-3. PubMed ID: 2606278 [No Abstract] [Full Text] [Related]